Positive Clinical Data Presented at US Dental Sleep Meeting
- Significant interest in encouraging results of pilot study presented at the American Academy of Dental Sleep Medicine in Boston.
- This was the first detailed physiological pilot study into the effect of the O2Vent TTM on pharyngeal pressure swings which cause the airway to collapse in Obstructive Sleep Apnoea and as a continuous positive air pressure (CPAP) interface.
- Encouraging data (n=4) supports the benefit of the Oventus Airway Technology by demonstrating clinical results comparable to traditional CPAP and when used in combination with a CPAP interface, significantly decreased the mask and pressure related complications - often the causal factor of CPAP failure or non-adherence.
- Trial has now progressed to an expanded study with recruitment of first patients as part of the CRC-P for sleep apnoea which received $2.95 million in non-dilutive government funding earlier this year - Oventus is the lead participant.
CPAP is the first line of treatment for sleep apnoeic patients and involves a pressure pump attached to a mask blowing air into the patient's airway. While not well tolerated, it is a multibillion dollar industry with massive unmet needs due to issues associated with current treatment options. In a potential paradigm shift in the treatment of this debilitating illness, the early data supports the use of the O2Vent TTM as a CPAP alternative either as a standalone appliance, or in combination with CPAP, using it as a strapless CPAP interface (no longer requiring high pressures or a mask).
Oventus founder and clinical director Dr Chris Hart said: "This was a major advancement in the ever-expanding range of sleep apnoea solutions using Oventus Airway Technology. A high percentage of complications and non-compliance with traditional CPAP are due to mask and pressure related issues - both minimised with the Oventus solution."
Sleep disorder device manufacturer and developer Oventus Medical is developing a treatment solution, addressing the treatment needs of the full spectrum of obstructive sleep apnoea disease severity - potentially changing the paradigm of care.
Dr Hart added: "The process to optimise the CPAP interface will be completed in the expanded trial. It's expected to be finished by the end of the year. Another trial is now under way in Perth, focussing on specific pressure and flow measurements in the patient's airway and how the Oventus Airway Technology influences this."
The clinical trial results from these two studies will also enable the development of a wearable micro PAP.
Notes: Continuous Positive Airway Pressure (CPAP)
To view tables and figures, please visit:
About Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane, Australia, based medical device company that is commercialising a new 'Sleep Treatment Platform' for the treatment of sleep apnoea and snoring. The Oventus platform enhances the treatment outcomes of both standard mouthguard-type oral appliance therapy (often used to treat mild to moderate sleep apnoea) and of Continuous Positive Airway Pressure (CPAP) therapy (often used to treat moderate to severe patients.)
Since the Oventus 'Sleep Treatment Platform' is generally well tolerated by patients, and incorporates a unique airway, which supports better breathing, it has been shown in clinical trials to have increased efficacy and provide greater adherence over the competing treatment options.
For more information on Oventus' Sleep Treatment Platform, please visit http://www.oventus.com
Oventus Medical Ltd